Rituximab-to-vaccine interval on SARS-CoV-2 immunogenicity in children: The potential role of prior natural infection.
Renato GualtieriSabine YerlyStephanie Garcia-TarodoPaloma ParvexNathalie RockKlara Posfay-BarbeArnaud M DidierlaurentChristiane Sigrid EberhardtGeraldine Blanchard-RohnerPublished in: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2024)
A past infection with SARS-CoV-2 may induce anti-RBD-specific memory B cells that can be re-activated by SARS-CoV-2 vaccination, even after rituximab-induced B-cell depletion. This suggests that it is possible to vaccinate earlier than 6 months after rituximab to develop a good antibody response, especially in the case of past SARS-CoV-2 infection.